- PK Data from Drug-Drug Interaction Study Describes Lack of CYP3A4 Interactions
The new Tesaro ovarian cancer drug will be marketed under the brand name Zejula.
AstraZeneca's PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo.
Shares were up 8% during intraday trading.
Here's a closer look at four of venture capital funds' favorite publicly traded names in 2017.